Table 1.
Epidemiological and clinical-pathologic features of 67 metastatic thyroid cancer patients
| 67 patients | |
|---|---|
| Age at time of last evaluation (years) (median) [IQR, intervals] | 62.5 [52–71.75, 28–91] |
| Sex | 26 female: 41 male |
| Histotypes—no (%) | |
| MTC | 35 (48.6%) |
| PTC | 13 (18.1%) |
| FTC | 12 (16.7%) |
| PDTC | 7 (9.7%) |
| Metastatic sites—no (%) | |
| Lymph node | 56 (83.6%) |
| Lung | 48 (71.6%) |
| Liver | 30 (45.5%) |
| Bone | 27 (40.3%) |
| Central nervous system | 9 (13.6%) |
| Cardiovascular comorbidities—no (%) | |
| Total | 44 (65.7%) |
| Major adverse cardiovascular events | 12 (17.9%) |
| Hypercholesterolemia | 8 (11.9%) |
| Arterial hypertension | 38 (56.7%) |
| Diabetes—no (%) | 5 (7.5%) |
| Asthma/COPD—no (%) | 4 (6.2%) |
| ECOG status at last evaluation—no (%) | |
| Grade 0 | 35 (52.2%) |
| Grade 1 | 23 (34.3%) |
| Grade 2 | 9 (13.4%) |
| Surgery—no (%) | |
| Thyroidectomy | 26 (39.4%) |
| Thyroidectomy + lymph node dissection | 40 (60.6%) |
| Radiotherapy—no (%) | 23 (34.3%) |
| Radioiodine therapy—no (%) | 32 (48.5%) |
| Radioiodine cumulative dose (mCi) | |
| Median | 278 |
| IQR | 127.75–561.25 |
| Intervals | 30–849.5 |
| Actual MKI—no (%) | |
| Vandetanib | 25 (34.7%) |
| Lenvatinib | 29 (40.3%) |
| Cabozantinib | 4 (5.6%) |
| Selpercatinib | 8 (11.1%) |
| Sunitinib | 1 (1.4%) |
| Number of MKIs for each patient—no (%) | |
| 1 | 51 (76.1%) |
| 2 | 8 (11.9%) |
| 3 | 7 (10.4%) |
| 4 | 1 (1.5%) |
| Total duration of MKIs treatment (months) (median) [IQR, intervals] | 46 [23–108, 3–156] |
| Duration of actual MKI (months) (median) [IQR, intervals] | 32 [12–96, 2–156] |
IQR interquartile range, MTC medullary thyroid cancer, PTC papillary thyroid cancer, FTC follicular thyroid cancer, PDTC poorly differentiated thyroid cancer, COPD chronic obstructive pulmonary disease, MKIs Multikinase inhibitors